Meridian submits Curian™ analyzer and the Curian™ HpSA assay to the FDA
November 06, 2019 07:30 ET
|
Meridian Bioscience Inc.
CINCINNATI, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that it has submitted Curian™ and the Curian™ HpSA assay to the FDA for review. This platform...
Meridian Bioscience to Hold Fourth Quarter and Full Year 2019 Financial Results Conference Call on November 7, 2019
October 16, 2019 11:00 ET
|
Meridian Bioscience Inc.
CINCINNATI, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials will report fourth quarter and full...
Meridian Bioscience Reports Third Quarter 2019 Operating Results
July 30, 2019 07:30 ET
|
Meridian Bioscience Inc.
CINCINNATI, Ohio, July 30, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter and first nine months ended June 30, 2019. Third...
Meridian Bioscience to Hold Third Quarter 2019 Financial Results Conference Call on July 30, 2019
July 10, 2019 16:30 ET
|
Meridian Bioscience Inc.
CINCINNATI, July 10, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials will report third quarter 2019...
Meridian Bioscience Announces Closing of Transaction to Acquire Business of GenePOC
June 03, 2019 16:28 ET
|
Meridian Bioscience Inc.
CINCINNATI, June 03, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced it has completed...
Meridian Bioscience Reports Second Quarter 2019 Operating Results, Suspends Quarterly Cash Dividend, and Provides Fiscal 2019 Guidance for Pending Acquisition
April 30, 2019 09:42 ET
|
Meridian Bioscience Inc.
CINCINNATI, April 30, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter and first six months ended March 31, 2019. Second...
Meridian Bioscience Announces Agreement to Acquire Business of GenePOC; Adds State-of-the-Art Molecular Diagnostics Platform
April 30, 2019 09:41 ET
|
Meridian Bioscience Inc.
CINCINNATI, April 30, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced it has entered...
Meridian Launches a New Inhibitor Tolerant qPCR Reagent to Significantly Simplify Molecular Diagnostic Workflows From Crude Samples
April 18, 2019 08:48 ET
|
Meridian Bioscience Inc.
CINCINNATI, April 18, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced the launch of its Inhibitor-tolerant qPCR Mix, a novel mix to accelerate workflows and improve...
Meridian Bioscience to Hold Second Quarter 2019 Financial Results Conference Call on April 30, 2019
April 10, 2019 16:55 ET
|
Meridian Bioscience Inc.
CINCINNATI, April 10, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials will report second quarter 2019...
Meridian Bioscience Announces Preliminary Second Quarter 2019 Revenue Results; Updates Fiscal 2019 Guidance
April 02, 2019 06:59 ET
|
Meridian Bioscience Inc.
CINCINNATI, April 02, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today provided a business update...